Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Use of rituximab in three children with relapsed/refractory Burkitt lymphoma.

Literature DB >> 20859698

Use of rituximab in three children with relapsed/refractory Burkitt lymphoma.

Sinan Akbayram¹, Murat Doğan, Cihangir Akgün, Fatih Erbey, Hüseyin Caksen, Ahmet Faik Oner.

Abstract

Monoclonal antibodies have provided new promise for patients with B-cell malignancies. Rituximab is a monoclonal antibody against B-lymphocytes that express CD20; it is used for the treatment of patients with relapsed or refractory B-cell non-Hodgkin lymphoma. Very few data are available regarding the treatment of children with non-Hodgkin lymphoma with rituximab. In this article, we reported three children with primary refractory/relapsed B-cell-non-Hodgkin lymphoma, who were successfully treated with a combination of intensive chemotherapy protocol plus rituximab. In all three of our cases, the patients are still in complete remission. Our aim is to emphasize the importance of use of rituximab in the treatment of childhood B-cell non-Hodgkin lymphoma.

Entities: Chemical Disease Gene Species

Mesh：

Substances：

Year: 2010 PMID： 20859698 DOI： 10.1007/s11523-010-0161-6

Source DB: PubMed Journal: Target Oncol ISSN： 1776-2596 Impact factor: 4.493

25 in total

1. Rituximab in a child with relapsed Burkitt lymphoma.

Authors: Ali Bay; Murat Dogan; Mehmet Acikgoz; Ahmet Faik Oner
Journal: Pediatr Blood Cancer Date: 2007-08 Impact factor: 3.167

2. Induction of long-term remission of a relapsed childhood B-acute lymphoblastic leukemia with rituximab chimeric anti-CD20 monoclonal antibody and autologous stem cell transplantation.

Authors: Selim Corbacioglu; Stefan Eber; Tayfun Gungor; Jorg Hummerjohann; Felix Niggli
Journal: J Pediatr Hematol Oncol Date: 2003-04 Impact factor: 1.289

3. Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma.

Authors: J M Vose; B K Link; M L Grossbard; M Czuczman; A Grillo-Lopez; P Gilman; A Lowe; L A Kunkel; R I Fisher
Journal: J Clin Oncol Date: 2001-01-15 Impact factor: 44.544

Review 4. Non-Hodgkin's lymphoma in childhood.

Authors: J T Sandlund; J R Downing; W M Crist
Journal: N Engl J Med Date: 1996-05-09 Impact factor: 91.245

5. Epstein-Barr virus-associated lymphoma in a child undergoing an autologous stem cell rescue.

Authors: John A Heath; Emmett H Broxson; Mukund G Dole; Daniel A Filippa; Diane George; David Lyden; Ira J Dunkel
Journal: J Pediatr Hematol Oncol Date: 2002-02 Impact factor: 1.289

6. Treatment of childhood autoimmune haemolytic anaemia with rituximab.

Authors: P Quartier; B Brethon; P Philippet; J Landman-Parker; F Le Deist; A Fischer
Journal: Lancet Date: 2001-11-03 Impact factor: 79.321

7. Rituximab as monotherapy and in addition to reduced CHOP in children with primary immunodeficiency and non-Hodgkin lymphoma.

Authors: Shimrit Shabbat; Jonas Aharoni; Liat Sarid; Miriam Ben-Harush; Joseph Kapelushnik
Journal: Pediatr Blood Cancer Date: 2009-05 Impact factor: 3.167

8. A study of rituximab and ifosfamide, carboplatin, and etoposide chemotherapy in children with recurrent/refractory B-cell (CD20+) non-Hodgkin lymphoma and mature B-cell acute lymphoblastic leukemia: a report from the Children's Oncology Group.

Authors: Timothy C Griffin; Sheila Weitzman; Howard Weinstein; Myron Chang; Mitchell Cairo; Robert Hutchison; Bruce Shiramizu; Joseph Wiley; Deborah Woods; Margaret Barnich; Thomas G Gross
Journal: Pediatr Blood Cancer Date: 2009-02 Impact factor: 3.167